Podcast 15 Dec 2023
Vaxxinity making vaccines to change the world
Discover how Vaxxinity’s vaccine approach aims to democratize global health, potentially reshaping access to innovative treatments worldwide.
Vaccines
- Latest Posts
In Depth 30 Nov 2023
Could an Alzheimer’s vaccine make treatment more affordable?
Alzheimer’s research has come a long way since the disease was first identified more than a century ago. Now, as treatments have been developed to reduce the harmful proteins in the brain that are associated with Alzheimer’s, vaccine trials are underway to eliminate these proteins. But how far along are these vaccines in the clinic? […]
Podcast 17 Nov 2023
How can life-saving vaccines be more affordable?
Phenotypeca, a biotech business from Nottingham, UK, has been working with the Bill & Melinda Gates Foundation to produce albumin for low and middle-income countries (LMICs), offering a catalyst for making life-saving vaccines affordable globally. Global vaccine production faces several challenges. Limited availability and the high costs associated with recombinant albumin act as a barrier […]
Best in Biotech 7 Nov 2023
Eight biotech companies tackling infectious diseases head-on
Infectious diseases are diseases that are caused by pathogens that enter the body, hijack the body’s immune system and multiply, causing an infection. Five of the deadliest infectious diseases are measles, tuberculosis, malaria, diarrhoeal disease and influenza, according to the World Economic Forum. While Our World in Data statistics suggest that there has been almost […]
In Depth 20 Oct 2023
Is Africa ready to become the next big biopharma and vaccine manufacturing destination?
Localizing pharma manufacturing worldwide is an extremely important step, and it holds particular significance for Africa. The continent is more vulnerable to disease burdens and lags behind other continents when it comes to vaccine and general healthcare access. Localized manufacturing could help people in Africa gain easier and more affordable access to vaccines and other […]
In Depth 11 Oct 2023
Project NextGen: The U.S. government’s $5 billion initiative to stay one step ahead of COVID-19
When SARS-CoV-2 spread out of Wuhan, China, to the rest of the world, it became only the fifth pandemic to be documented since the 1918 flu pandemic. As the entire world went into lockdown, waiting in anticipation for a miracle treatment, the scientific community accomplished what had never been accomplished before, developing first-of-their-kind vaccines against […]
ADVERTISEMENT
ADVERTISEMENT
In Depth 6 Oct 2023
Will the U.S. Cancer Moonshot program land its target to halve cancer death rates?
It was predicted that more than 600,000 people would die from cancer last year in the U.S., according to the American Cancer Society. But what if those figures could be halved over the next couple of decades? Although no small feat, that’s precisely what the Cancer Moonshot program aims to do. The White House initiative, […]
Podcast 29 Sep 2023
Beyond Biotech podcast 65 – Disease X and pandemic preparedness
Disease X, a concept shrouded in mystery, represents the unknown pathogens that could unleash future epidemics or pandemics. In the wake of recent global health crises, our understanding of the profound impact of those pandemics has deepened. On this week’s podcast, we have a conversation with Hamilton Bennett, who led Moderna’s mRNA-1273 COVID-19 vaccine development […]
In Depth 16 Aug 2023
Can a vaccine be the solution to the surge in melanoma cases caused by the climate crisis?
Melanoma is the most serious type of skin cancer, and is primarily caused by too much exposure to ultraviolet (UV) light – in the U.K., around 85% of melanomas are thought to be caused by too much ultraviolet radiation. And, unfortunately, because of this, the surge in global temperatures caused by the climate crisis is […]
Podcast 4 Aug 2023
Beyond Biotech podcast 57: Group B Strep
To recognize International Group B Strep Awareness Month in July, we had a conversation with MinervaX CEO, Per Fischer. MinervaX is a privately-held Danish biotechnology company developing a novel prophylactic vaccine against Group B streptococcus (GBS), with two phase II clinical trials ongoing in pregnant women and a phase I clinical trial ongoing in older adults. Due […]
News and Trends 28 Jul 2023
New CHAIN Biotech funding to aid CADD therapeutic platform
CHAIN Biotechnology Limited has developed a therapeutic approach based on engineering a probiotic strain of Clostridium to deliver oral vaccines and therapeutics. Its Clostridium Assisted Drug Development platform (CADD) technology is a live therapeutic that employs a triple mode of action, incorporating mucosal and systemic immune responses alongside microbiome enhancement, and is delivered via stable, […]
News and Trends 27 Jul 2023
Recbio shingles vaccine clinical trial approved
Jiangsu Recbio Technology Co., Ltd. has received notice of acceptance from China’s National Medical Products Administration (NMPA) to start a clinical trial for its self-developed novel adjuvanted recombinant shingles vaccine, REC610. Within 60 days from the date of acceptance, the company may carry out clinical trials in accordance with the submitted plan if no negative […]
ADVERTISEMENT
